MannKind | MNKD - Процентные расходы





Процентные расходы Изменить Дата
Adma Biologics USD 1.63M 54K 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Halozyme Therapeutics USD 5.51M 597K 2026-03
Insmed USD 20.08M 517K 2026-03
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
MannKind USD 12.43M 1.44M 2026-03
Merck USD 479M 67M 2026-03
Minerva Neurosciences USD 2.31M 60K 2024-06
Novavax USD 5.82M 342K 2025-12
Pfizer USD 671M 40M 2026-03
Sanofi EUR 178M 203M 2026-03
Xencor USD 4.7M 2.65M 2026-03